Biochemical Insights and Clinical Applications of Ischemia-Modified Albumin in Ischemic Conditions

The document reviews the role of ischemia-modified albumin (IMA) as an early biomarker for ischemic conditions, particularly myocardial ischemia. IMA can be detected within 6-10 minutes of an ischemic event and remains elevated for 12 hours, offering potential for early diagnosis. However, current detection methods like the Albumin Cobalt Binding (ACB) assay face challenges in reproducibility and accuracy. The review emphasizes the need for further research to improve detection methods and validate IMA's clinical utility across different disease states. Advanced techniques such as ELISA and XRF spectroscopy show promise in enhancing detection accuracy but are costly and require specialized equipment.